US/UK/Canada

Share

About Us

ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.

Contacts

  • ChromoGenics
    Ullforsgatan 15, 752 28 Uppsala
    +46 18 43 00 430
    http://www.chromogenics.com
    • Pick a time period -
    Tags ( Active)

    Avnotering av ChromoGenics AB (publ) från Nasdaq First North Stockholm

    Enligt beslut av Nasdaq First North Stockholm kommer ChromoGenicsAB (publ) att avnoteras från Nasdaq First North Stockholm. Sista handelsdag i aktien blir måndagen den 30 september 2024. För ytterligare information kontakta: Fredrik Fränding, VDE-post: fredrik.franding@chromogenics.com Telefon: +46 (0) 72 249 24 62 Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 16 september 2024 kl. 16:45 CEST. Om ChromoGenics ChromoGenics AB (publ) är ett proptechbolag som framställer smart dynamiskt glas som förbättrar inomhusmiljö och

    ChromoGenics Interim Report January–June 2024

    Key events during Q2 2024 During the first half of 2024, ChromoGenics continued its developmental journey with a strong focus on the customer and quality, continued to take measures to lower costs, and received an order for the manufacture of ConverLight® Dynamic from one of the company’s new European partners for a non-European customer. · ChromoGenics announced that it held an Extraordinary General Meeting, at which the Meeting resolved to approve the Board’s decision according to the above on directed issues of shares and therewith related proposals. The Extraordinary General

    ChromoGenics AB (publ): Bulletin from the annual general meeting held on 25 June 2024

    ChromoGenics AB ("ChromoGenics" or the "Company") has today, on 25 June 2024, held its annual general meeting. The annual general meeting in ChromoGenics resolved, among other things, as follows. The notice to the annual general meeting and the complete proposals are available on the Company's website, www.chromogenics.com. Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual general meeting resolved to approve the profit and loss accounts and balance sheets for the financial year 2023 and the

    ChromoGenics AB (publ) publishes the Annual Report for 2023

    ChromoGenics AB  (publ) today announces that it has published the Annual Report for 2023.The Annual Report, which is attached to the press release, is also available on the company website, https://chromogenics.com/annual-reports/The Annual Report can also be ordered from the company and distributed by post to the shareholders who request it.  Contact: Fredrik Fränding, CEOAnne-Marie Gullman, CFO & Head of Investor RelationsTel: +46 (0) 18 430 0430 E-mail: info@chromogenics.com ChromoGenics This statement has been made in a Swedish and

    ChromoGenics announces a conditional loan of 47,6 MSEK is converted to a grant

    ChromoGenics announces a conditional loan of 47,6 MSEK is converted to a grant The Swedish Energy Agency changes its decision from November 29, 2012, so that support in the form of an advance with repayment obligation to ChromoGenics AB (Conditional Loan) is now converted to a grant. On November 29, 2012, ChromoGenics AB was granted support to carry out a project by the Energy Agency. The support was provided in the form of an advance with a repayment obligation (Conditional Loan), which is a loan where the repayment conditions depend on the project's outcome. The Swedish Energy

    NOTICE TO ANNUAL GENERAL MEETING IN CHROMOGENICS AB

    Shareholders of ChromoGenics AB, reg. no 556630-1809 are hereby summoned to the annual general meeting to be held on 25 June 2024 at 10.00 CEST at Clarion Hotel Gillet on Dragarbrunnsgatan 23 in Uppsala.The registration to the meeting will open at 9.30 CEST. Right to participate and notice of participation A shareholder who wishes to participate at the annual general meeting must: (i) be recorded in the share register maintained by Euroclear Sweden AB on 14 June 2024, and(ii) notify the company of its intention to participate by post to ChromoGenics AB,

    Interim Report January – March 2024

    ChromoGenics delivers dynamic glass to the head office of the Swedish National Board of Housing, Building & Planning Quarter 1, 2024 · · · · ChromoGenics’ net sales for Q1 2024 amounted to SEK 2.8 (5.8) million. The decrease can be primarily linked to the completion of two major projects in the first quarter of the previous year, Franska skolan i Copenhagen and Duvan in Uppsala, for which there was no equivalent this year. · Order intake in the first quarter amounted to SEK 2.2 (2.4) million, and the decrease can be primarily linked to the challenging

    ChromoGenics announces new date for its annual general meeting and annual report 2023

    2024-04-08 Uppsala, Sweden – ChromoGenics, a leading provider of dynamic glass solutions, announces that the Board of Directors has decided to reschedule the company’s annual general meeting from May 28[th] 2024 to June 25[th] 2024. The submission of the annual report 2023 will also be altered from 25[th] April to 4[th] June 2024.  ContactFredrik Fränding, CEOAnne-Marie Gullman, CFO & Head of Investor RelationsTel: +46 (0) 18 430 0430E-mail: info@chromogenics.comChromoGenics   About ChromoGenics ChromoGenics is a proptech company that

    ChromoGenics AB (publ) announces allocation in directed share issue

    On 5 March 2024 ChromoGenics AB (publ) ("ChromoGenics" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the extraordinary general meeting, on a directed issue of 2,505,885 shares in a total amount of SEK 16 million (the "Directed Issue"). The subscription price amounted to SEK 6.44 per share and was determined based on an accelerated bookbuilding procedure carried out by Vator Securities AB (acting as Sole Bookrunner). The subscribers in the Directed Issue consist of existing shareholders, including the Company's two largest

    ChromoGenics AB (publ): Bulletin from the Extraordinary General Meeting on 5 April 2024

    ChromoGenics AB (publ) (the "Company") has today, on 5 April 2024, held an Extraordinary General Meeting. The Extraordinary General Meeting resolved to approve the Board of Directors' resolutions on directed issues of shares and there with related proposals. The notice to the Extraordinary General Meeting and the complete proposals are available on the Company's website, www.chromogenics.com. Directed share issues and there with related resolutions The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to approve the Board of Directors'

    ChromoGenics receives first order for North America

    ChromoGenics secures first order for North America: Bringing Dynamic Glass to luxury villa project in Colorado.Uppsala, Sweden. ChromoGenics, a leading provider of dynamic glass solutions, announces its inaugural order for the North American market. The company has been chosen to supply its innovative ConverLight® Dynamic Glass to a luxury villa project in Colorado, USA. The villa, emphasizing sustainability and energy efficiency, will feature windows supplied by ChromoGenics' German partner, ENERsign. The project is managed and delivered by ENERsign, a German manufacturer of high-

    ChromoGenics initiates cost reduction program

    ChromoGenics adjusts cost structure to meet market challenges and ensure long-term growth. Stockholm, 2024-03-25 - ChromoGenics (NASDAQ: CHRO), a leading supplier of dynamic glass products and solutions, announced today the decision to adjust its cost structure to address market challenges and ensure long-term growth. Over the past year, ChromoGenics has achieved significant improvements in its production process, resulting in increased efficiency and enhanced production capacity. The production processes are stable and contribute to a positive gross margin, providing a solid

    Year-End Report January 1– December 31, 2023

    ChromoGenics wins prestigious project from Skanska – Swedish National Board of Housing, Building and Planning’s new head office   Q4 2023 ChromoGenics’ order intake for Q4 2023 was SEK 6.6 (2.8) million, an increase of SEK 3.8 million compared to the corresponding period the previous year. During the second half of 2023, the company has improved order intake significantly compared to the previous quarter. For example, during the fall the company received an assignment from Skanska to deliver dynamic glass to the Swedish National Board of Housing, Building and Planning's new head

    NOTICE TO EXTRAORDINARY GENERAL MEETING IN CHROMOGENICS AB (PUBL)

    Shareholders of ChromoGenics AB (publ), reg. no 556630-1809, are hereby summoned to the extraordinary general meeting to be held on 5 April 2024 at 10.00 CEST at Clarion Hotel Gillet on Dragarbrunnsgatan 23 in Uppsala. The registration to the meeting will open at 9.30 CEST. Right to participate and notice of participation A shareholder who wishes to participate at the extraordinary general meeting must: (i) be recorded in the share register maintained by Euroclear Sweden AB on 26 March 2024, and(ii) notify the company of its intention to participate by post to

    CHROMOGENICS HAS SUCCESSFULLY COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 16 MILLION

    The board of directors of ChromoGenics AB (publ) (”ChromoGenics” or the ”Company”) has today, subject to subsequent approval by the extraordinary general meeting on 5 April 2024, resolved on a directed issue of 2,505,885 shares (the ”Directed Issue”). The subscription price amounts to SEK 6.44 per share and was determined based on an accelerated bookbuilding procedure carried out by Vator Securities AB (acting as Sole Bookrunner). The subscribers in the Directed Issue consist of existing shareholders, including the Company's two largest shareholders Färna Invest AB and Parment Förvaltning

    Chromogenics evaluates the conditions for carrying out a directed issue of shares

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN CHROMOGENICS AB. SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW. CHROMOGENICS EVALUATES THE CONDITIONS FOR CARRYING OUT A DIRECTED ISSUE OF SHARES The Board of Directors of ChromoGenics AB (publ) ("

    ChromoGenics' Dynamic Glass in Boverket's New Headquarters

    In a groundbreaking project with stringent environmental performance requirements, Skanska is building the new headquarters for the Swedish National Board of Housing, Building and Planning, “Boverket” in Karlskrona. The building is a pilot project and sets an entirely new standard for future sustainable office properties, with the choice of dynamic glass being ChromoGenics' latest innovation, ConverLight. ChromoGenics has now initiated production of the glass. Swedish Building Regulations are issued by Boverket. Along the waterfront in Karlskrona, construction has begun on Boverket's new

    ChromoGenics communicates order data for the fourth quarter in 2023 and postpones publication of the year-end report for 2023.

    ChromoGenics order intake for the fourth quarter 2023 amounted to 6,6 MSEK and the order book for the same period was 11,5 MSEK. Due to unexpected administrative reasons, the Board of Directors of ChromoGenics has decided to postpone the publication of the year-end report for 2023 until 8[th] of March 2024. Previously communicated date for submission of the report was on the 20[th] of February 2024. Full data on the fourth quarter 2023 will be published in the year-end report. Contact: Fredrik Fränding, CEOAnne-Marie Gullman, CFO & Head of Investor RelationsTel: +46 (0) 18

    ChromoGenics will deliver Dynamic Glass to an office building in Sweden

    ChromoGenics will deliver ConverLight dynamic glass to an office building in Sweden. Expected total order value is 6 MSEK.The product, ConverLight, is an advanced technology where an electrochromic film is laminated into the glass to regulate the intensity of sunlight and heat penetration into buildings. The solution improves indoor comfort and wellbeing, and reduces energy consumption, operational costs and the environmental footprint of the property. When the sun shines, the control system darkens the glass, significantly reducing the need for air conditioning. Similarly, solar heat

    Interim Report January–September 2023

    ChromoGenics increases order intake and continues to lower costsQ3 2023 (July–September) · Net sales amounted to SEK 1.6 (3.5) million, a decrease of SEK 1.9 million compared to the corresponding quarter in 2022. · Operating costs excluding depreciation and amortization and financial expenses amount to SEK 12.2 (22.0) million in Q3 2023 and correspond to a decrease in costs of SEK 9.7 million or 44 percent. · Earnings before tax, depreciation/amortization and financial items (EBITDA) improved in the quarter by SEK 2.5 million and amount to SEK -9.2 (-11.7) million. · Cash flow

    ChromoGenics announces the outcome of exercised warrants of series TO 6

    The board of directors of ChromoGenics AB (publ) ("ChromoGenics" or the "Company") today announces the outcome of the exercise period for warrants series TO 6 (the "Warrants") that were issued in connection with ChromoGenics' rights issue of units that was announced on 17 May 2023 (the "Rights Issue"). The Warrants were subscribed to approximately 0.25 percent. In total, ChromoGenics will receive approximately SEK 51 thousand before issue costs. Within the framework of the Rights issue, ChromoGenics issued 240,222,962 Warrants.  The Company has, following the Rights Issue, carried out a

    ChromoGenics postpones publication of the financial report for the third quarter in 2023

    The Board of Directors of ChromoGenics has decided to postpone the publication of the financial report for the third quarter in 2023.For practical reasons, the Board of Directors of ChromoGenics has decided to postpone the publication of the third quarterly report in 2023 until the 30[th] of November 2023. Previously communicated date for submission of the report was on the 23[rd] of November 2023. Contact: Fredrik Fränding, CEOAnne-Marie Gullman, CFO & Head of Investor Relations Tel: +46 (0) 18 430 0430E-mail: info@chromogenics.com ChromoGenics This information was

    The last day for trading in the warrants to 6 is today, 15 november 2023

    Today, 15 November 2023, is the last day for trading in warrants of series TO 6 (the "Warrants"), which were issued in connection with ChromoGenics AB's ("ChromoGenics" or the "Company") rights issue of units announced on 17 May 2023 (the "Rights Issue"). Note that Warrants not sold by today, 15 November 2023, or alternatively exercised to subscribe for shares no later than 20 November 2023, expire without value. In connection with the Rights Issue, ChromoGenics issued 240,222,962 Warrants. The exercise period of the Warrants started on 6 November 2023, and ends on 20 November 2023. The

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Youtube